>
Switch to:

Ovid Therapeutics Graham Number

: $10.73 (As of Jun. 2021)
View and export this data going back to 2017. Start your Free Trial

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2021-10-21), the stock price of Ovid Therapeutics is $3.62. Ovid Therapeutics's graham number for the quarter that ended in Jun. 2021 was $10.73. Therefore, Ovid Therapeutics's Price to Graham Number ratio for today is 0.34.

The historical rank and industry rank for Ovid Therapeutics's Graham Number or its related term are showing as below:

NAS:OVID' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.34   Med: 0.37   Max: 0.38
Current: 0.34

0.34
0.38

During the past 6 years, the highest Price to Graham Number ratio of Ovid Therapeutics was 0.38. The lowest was 0.34. And the median was 0.37.

NAS:OVID's Price-to-Graham-Number is ranked lower than
99.99% of the 23 Companies
in the Biotechnology industry.

( Industry Median: 3.05 vs. NAS:OVID: 0.34 )

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


Ovid Therapeutics Graham Number Historical Data

The historical data trend for Ovid Therapeutics's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovid Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Graham Number
Premium Member Only - - - - -

Ovid Therapeutics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Graham Number Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 10.49 10.73

Competitive Comparison

For the Biotechnology subindustry, Ovid Therapeutics's Graham Number, along with its competitors' market caps and Graham Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Ovid Therapeutics Graham Number Distribution

For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Graham Number distribution charts can be found below:

* The bar in red indicates where Ovid Therapeutics's Graham Number falls into.



Ovid Therapeutics Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

Ovid Therapeutics's Graham Number for the fiscal year that ended in Dec. 2020 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*0.659*-1.39)
=N/A

Ovid Therapeutics's Graham Number for the quarter that ended in Jun. 2021 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*3.044*1.68)
=10.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ovid Therapeutics  (NAS:OVID) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

Ovid Therapeutics's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Jun. 2021 )
=3.62/10.73
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


Ovid Therapeutics Graham Number Related Terms

Thank you for viewing the detailed overview of Ovid Therapeutics's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


Ovid Therapeutics Business Description

Ovid Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
1460 Broadway, Suite 15044, New York, NY, USA, 10036
Ovid Therapeutics Inc is a US based biopharmaceutical company. The firm is primarily engaged in developing impactful medicines for patients and families living who are suffering with rare neurological disorders. It is targeting disorders such as intellectual disability, severe speech impairment, problems with movement and balance, sleep disorders and anxiety to transform the patient's life.
Executives
Rona Jeffrey A officer: Chief Business Officer 500 PLAZA DRIVE SECAUCUS NJ 07094
Haasner Dirk officer: SVP, Global Regulatory Affairs C/O OVID THERAPEUTICS INC. 1460 BROADWAY, SUITE 15044 NEW YORK NY 10036
Perone Thomas Michael officer: General Counsel, Secretary 1460 BROADWAY NEW YORK NY 10036
Levin Jeremy M director, 10 percent owner, officer: CEO PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: LEVIN JEREMY M a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Tardio Jason officer: Chief Commercial Officer 1460 BROADWAY NEW YORK NY 10036
Williams Douglas E director C/O AMGEN INC ONE AMGEN CENTER DR THOUSAND OAKS CA 91320-1799
Duncan Barbara Gayle director C/O INTERCEPT PHARMACEUTICALS, INC. 18 DESBROSSES STREET NEW YORK NY 10013
Friedman Bart director ALLIED WORLD ASSURANCE CO HOLDINGS, LTD 43 VICTORIA STREET HAMILTON D0 HM 12
Bernstein Karen director C/O VITAE PHARMACEUTICLS, INC. 502 WEST OFFICE CENTER DRIVE FORT WASHINGTON PA 19034
Daly Timothy officer: EVP,Finance & Corp. Controller 20 KINGSBRIDGE ROAD PISCATAWAY NJ 08854
Rakhit Amit officer: President and CMO C/O OVID THERAPEUTICS INC. 1460 BROADWAY, SUITE 15044 NEW YORK NY 10036
Millennium Pharmaceuticals Inc 10 percent owner 40 LANDSDOWNE STREET CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668
During Matthew director, 10 percent owner, officer: President and CSO C/O OVID THERAPEUTICS INC. 1460 BROADWAY, SUITE 15044 NEW YORK NY 10036
Ward Ana officer: SVP and General Counsel C/O OVID THERAPEUTICS INC. 1460 BROADWAY, SUITE 15044 NEW YORK NY 10036

Ovid Therapeutics Headlines

Other Sources

3 Top Biotech Stocks to Buy Now

By Fool 2020-07-25

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)